Red Flag · First reading of the financial statement · AI-generated content HCA Red Flag: Novonesis maintains guidance, but Human Health outlook lowered again (AI)
HC Andersen Capital
Tiivistelmä
- Novonesis maintained its guidance despite lowering the Human Health outlook for the second time this year, with the division's performance falling 8% against an expected 5.1% decline.
- Probiotics and dietary supplements sales declined in Q3 due to a weak North American market, leading to a revised expectation of a slight decline in 2026.
- Free cash flow decreased by 31% in the quarter, impacted by higher receivables and inventories, with investments and financing costs expected at the high end of their respective ranges.
- Food & Beverages outperformed expectations with a 14% growth, driven by demand for protein-rich dairy products, contributing to an adjusted EBITDA margin increase to 38.5%.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in Danish 05/11/2026, 07:07 GMT. Give feedback here.
| Red Flag · First read of the financial statement · AI-generated content HCA Red Flag: Novonesis maintains guidance, but Human Health expectation is lowered again (AI) Novonesis (NSIS B) · 9M 2026 · November 5 The share +9% in three months, 5% below the 52-week peak |
Overall assessment: Slightly negative assessment
| Positive view | Balanced | Negative view |
The share should open slightly lower: Human Health fell 8% vs. the expected 5.1%, and the outlook for the division is lowered for the second time this year. The offsetting factor is organic growth – i.e., excluding foreign exchange and acquisitions – of 6% vs. the expected 5.9% and maintained guidance.
Red flags in the financial statement
Human Health outlook lowered for the second time this year
Actual −8% vs. Expected −5.1%
Probiotics and dietary supplements, accounting for around a tenth of sales, fell organically in Q3 in a weak North American market. The company now expects a slight decline in 2026; in August, the guidance was for slight growth.
Planetary Health below expectations in both areas
Household Care 4% vs. Expected 5.6%
Agriculture, Energy & Tech grew 4% vs. the expected 5.0%, of which just under 2 percentage points came from the expected inventory reduction in Animal. The division is still expected to come in at the low-end of the group's range.
Free cash flow fell 31% in the quarter
EUR 249.5 million · Last year EUR 361.3 million
Cash flows before acquisitions were weighed down by higher receivables and inventories. Investments are expected at the high end of 12% to 14% of sales, and financing costs at the high end of EUR 80 to 90 million.
Green flags in the financial statement
Food & Beverages clearly beat expectations
Actual 14% vs. Expected 11.4%
Food cultures and enzymes grew on demand for protein-rich dairy products and cheese. The adj. EBITDA margin in Food & Health rose by 4.0 percentage points to 38.5%.
Highest margin of the year in a quarter
Actual 38.3% vs. Expected 38.0%
The adj. EBITDA margin, operating profit before depreciation as a percentage of sales, rose by 1.2 percentage points from 37.1%. Adj. EBITDA grew 11% to EUR 437.1 million.
Guidance maintained with high single-digit growth in Q4
Guidance 7% to 8% · Expected 7.5%
After 7% in the first nine months, the company points to high single-digit growth in Q4. The effect of the withdrawal from certain countries, of around 1.5 percentage points in H1, is gone.
Disclaimer: This is an HCA AI-generated research commentary based solely on the company's published financial statements. The commentary does not constitute investment consulting and should not be used as the sole basis for investment decisions. Investing in shares involves the risk of loss. Seek professional consulting. /HC Andersen Capital, 08:05, November 5, 2026
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille